Quote | Humacyte Inc. (NASDAQ:HUMA)
Last: | $8.26 |
---|---|
Change Percent: | -6.03% |
Open: | $8.58 |
Close: | $8.79 |
High: | $8.65 |
Low: | $7.91 |
Volume: | 3,738,990 |
Last Trade Date Time: | 07/17/2024 03:00:00 am |
News | Humacyte Inc. (NASDAQ:HUMA)
2024-07-17 06:49:52 ET Summary Humacyte is developing HAVs for multiple indications, showing promising clinical outcomes, and receiving FDA RMAT designation for faster approval processes. The market for vascular repairs is large and growing, with Humacyte's HAVs positioned as a po...
DURHAM, N.C., July 16, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, announced the addition of pharmaceutical industry veteran Dr. John P. Bamforth and di...
Message Board Posts | Humacyte Inc. (NASDAQ:HUMA)
Subject | By | Source | When |
---|---|---|---|
znewcar1: HUMA 26% v3,4M c4.40 f103M H4.53 ML3.2 | znewcar1 | investorshangout | 08/12/2022 2:04:10 AM |
Piper Sandler price target, $17 | Glider549 | investorshub | 09/16/2021 1:44:20 PM |
YEP! $$$ | Glider549 | investorshub | 09/09/2021 9:59:56 PM |
Anyone else here in $HUMA? | nsomniyak | investorshub | 09/05/2021 3:54:42 AM |
News, Short Squeeze, Breakout and More Instantly...
DURHAM, N.C., July 16, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, announced the addition of pharmaceutical industry veteran Dr. John P. Bamforth and di...
Pluristyx, a leading provider of tools, technologies, and services for the development of cellular therapies, is pleased to announce a license agreement with Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercia...
2024-07-01 10:28:20 ET Humacyte Inc (NASDAQ: HUMA) opened close to 25% up on Monday after the Food & Drug Administration granted its ATEV a special advanced-therapy designation. Shares of the biotech firm are still down some 30% versus their year-to-date high. Why does it ma...